Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• Programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) pathway upregulation is a key immune evasion mechanism in Epstein-Barr virus (EBV)-associated nasopharyngeal cancer (NPC).
• Targeting the PD-1/PD-L1 axis is a significant area of research for NPC treatment.
• At least 8 antibodies targeting this axis are in clinical evaluation for various NPC stages.

Purpose of the Study:

• To review the scientific rationale for targeting the PD-1/PD-L1 axis in NPC.
• To summarize current clinical trials investigating PD-1/PD-L1 inhibitors in NPC.
• To discuss predictive biomarkers for response to PD-1/PD-L1 therapies in NPC.

Main Methods:

• Review of scientific literature and clinical trial data.
• Analysis of therapeutic strategies involving PD-1/PD-L1 antibodies in NPC.
• Evaluation of combinatorial approaches with chemotherapy, radiotherapy, and other immunotherapies.

Main Results:

• PD-1 antibodies as monotherapy show objective response rates of 20-30% in patients with recurrent/metastatic (R/M) NPC in Phase II trials.
• The predictive role of PD-L1 expression in NPC is still under investigation.
• Combinatorial strategies are actively being evaluated in various clinical trial designs.

Conclusions:

• Targeting the PD-1/PD-L1 axis represents a promising therapeutic strategy for EBV-associated NPC.
• Ongoing clinical trials are exploring various treatment settings and combinations.
• Further research is needed to define predictive biomarkers for optimal patient selection.